Review

. 2020 Jul:151:102975.

doi: 10.1016/j.critrevonc.2020.102975. Epub 2020 Apr 27.

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

A Belkouz¹, J W Wilmink¹, N Haj Mohammad², J Hagendoorn³, J de Vos-Geelen⁴, C H C Dejong⁵, M Y V Homs⁶, B Groot Koerkamp⁷, T M van Gulik⁸, M G H van Oijen¹, C J A Punt¹, H Klümpen⁹

Affiliations

¹ Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
² UMC Utrecht Cancer Center/RAKU, Dept. of Medical Oncology, Utrecht University, Utrecht, the Netherlands.
³ UMC Utrecht Cancer Center/RAKU, Dept. of Surgery, Utrecht University, Utrecht the Netherlands.
⁴ Maastricht UMC+, GROW - School for Oncology and Developmental Biology, Dept. Internal Medicine, Div. of of Medical Oncology, Maastricht, the Netherlands.
⁵ Department of Surgery and School of Nutrition and Translational Research in Metabolism, Maastricht UMC+, Maastricht, the Netherlands and Department of Surgery, Universitätsklinikum Aachen, Aachen, Germany.
⁶ Erasmus MC, Dept. of Medical Oncology, Rotterdam, the Netherlands.
⁷ Erasmus MC, Dept. of Surgery Rotterdam, the Netherlands.
⁸ Amsterdam UMC, Dept. of Surgery, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
⁹ Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands. Electronic address: h.klumpen@amsterdamumc.nl.

PMID: 32464483
DOI: 10.1016/j.critrevonc.2020.102975

Free article

Review

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

A Belkouz et al. Crit Rev Oncol Hematol. 2020 Jul.

Free article

. 2020 Jul:151:102975.

doi: 10.1016/j.critrevonc.2020.102975. Epub 2020 Apr 27.

Authors

A Belkouz¹, J W Wilmink¹, N Haj Mohammad², J Hagendoorn³, J de Vos-Geelen⁴, C H C Dejong⁵, M Y V Homs⁶, B Groot Koerkamp⁷, T M van Gulik⁸, M G H van Oijen¹, C J A Punt¹, H Klümpen⁹

Affiliations

¹ Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
² UMC Utrecht Cancer Center/RAKU, Dept. of Medical Oncology, Utrecht University, Utrecht, the Netherlands.
³ UMC Utrecht Cancer Center/RAKU, Dept. of Surgery, Utrecht University, Utrecht the Netherlands.
⁴ Maastricht UMC+, GROW - School for Oncology and Developmental Biology, Dept. Internal Medicine, Div. of of Medical Oncology, Maastricht, the Netherlands.
⁵ Department of Surgery and School of Nutrition and Translational Research in Metabolism, Maastricht UMC+, Maastricht, the Netherlands and Department of Surgery, Universitätsklinikum Aachen, Aachen, Germany.
⁶ Erasmus MC, Dept. of Medical Oncology, Rotterdam, the Netherlands.
⁷ Erasmus MC, Dept. of Surgery Rotterdam, the Netherlands.
⁸ Amsterdam UMC, Dept. of Surgery, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
⁹ Amsterdam UMC, Dept. of Medical Oncology, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands. Electronic address: h.klumpen@amsterdamumc.nl.

PMID: 32464483
DOI: 10.1016/j.critrevonc.2020.102975

Abstract

Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).

Keywords: Adjuvant therapy; Biliary tract cancer; Chemoradiotherapy; Chemotherapy; Cholangiocarcinoma; Neoadjuvant therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest H.K. is a member of the international steering committee of the ACTICCA-01 trial. Other authors declare that they have no conflict of interest.

Cited by

Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review.
Wijetunga I, McVeigh LE, Charalambous A, Antanaviciute A, Carr IM, Nair A, Prasad KR, Ingram N, Coletta PL. Wijetunga I, et al. Cancers (Basel). 2020 Sep 30;12(10):2817. doi: 10.3390/cancers12102817. Cancers (Basel). 2020. PMID: 33007872 Free PMC article. Review.
Adjuvant treatment for the elderly patient with resected gallbladder cancer: a SEER-Medicare analysis.
de Savornin Lohman E, Belkouz A, Nuliyalu U, Groot Koerkamp B, Klümpen HJ, de Reuver P, Nathan H. de Savornin Lohman E, et al. J Gastrointest Oncol. 2022 Dec;13(6):3227-3239. doi: 10.21037/jgo-22-348. J Gastrointest Oncol. 2022. PMID: 36636087 Free PMC article.
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
Luvira V, Satitkarnmanee E, Pugkhem A, Kietpeerakool C, Lumbiganon P, Pattanittum P. Luvira V, et al. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD012814. doi: 10.1002/14651858.CD012814.pub2. Cochrane Database Syst Rev. 2021. PMID: 34515993 Free PMC article.
Locally advanced cholangiolocellular carcinoma successfully treated with curative resection after downsizing chemotherapy: a case report.
Hozaka Y, Kawasaki Y, Iino S, Idichi T, Hirase Y, Tanoue K, Mataki Y, Kurahara H, Maemura K, Arigami T, Ueno S, Natsugoe S, Ohtsuka T. Hozaka Y, et al. Surg Case Rep. 2021 Jan 26;7(1):34. doi: 10.1186/s40792-021-01120-y. Surg Case Rep. 2021. PMID: 33496894 Free PMC article.
DWI-based radiomic signature: potential role for individualized adjuvant chemotherapy in intrahepatic cholangiocarcinoma after partial hepatectomy.
Yang Y, Zou X, Zhou W, Yuan G, Hu D, Shen Y, Xie Q, Zhang Q, Kuang D, Hu X, Li Z. Yang Y, et al. Insights Imaging. 2022 Mar 4;13(1):37. doi: 10.1186/s13244-022-01179-7. Insights Imaging. 2022. PMID: 35244793 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

Affiliations

Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources